Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky

Zevra investors who relied on public statements about arimoclomol's approval status faced losses after the July 24, 2026 negative opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use ("CHMP"). NEW YORK, Aug. 3, 2026 /PRNewswire/ -- On July 24,...